Saint Louis University receives NIH contract for omics research
Sequencing omics techniques and mass spectrometry will help the scientists to find four areas that may be vital to future information about how the immune responses work.
The contract will last for the next five years. The goal is to review RNA quality results in order to inspect purified T cells. This work is to prepare for the transcriptome analysis.
"We're building off genomics as we enter the omics revolution in our search for new safe and effective vaccines,” Daniel Hoft, principal investigator and director of the division of infectious diseases and immunology at Saint Louis University, said. “In particular, we're looking at how a host of systems trigger our bodies' immune response to protect us from infectious diseases.”
Many researchers consider this biology-based field of study as the new frontier for discovery in infectious diseases.
"Previously we could only measure a few endpoint responses, such as the presence of an antibody or T-cell responses to a specific antigen,” Hoft said. “But through omics studies, we will be able to use sophisticated technologies to determine all responses in the body necessary to marshal the immune system to best recognize and defend against bacteria, viruses and other harmful substances. This biological systems approach represents a new frontier of infectious diseases research."